QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
(Address Of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Page |
||||||
Item 1. | 1 | |||||
1 | ||||||
2 | ||||||
3 | ||||||
4 | ||||||
5 | ||||||
Item 2. | 16 | |||||
Item 3. | 20 | |||||
Item 4. | 20 | |||||
Item 1. | 20 | |||||
Item 1A. | 21 | |||||
Item 2. | 22 | |||||
Item 3. | 22 | |||||
Item 4. | 22 | |||||
Item 5. | 22 | |||||
Item 6. | 22 |
Item 1. |
Unaudited Financial Statements |
June 30, 2021 |
December 31, 2020 |
|||||||
(Unaudited) |
||||||||
Assets: |
||||||||
Current assets: |
||||||||
Cash |
$ | $ | ||||||
Prepaid expenses |
— | |||||||
|
|
|
|
|||||
Total current assets |
||||||||
Investments held in Trust Account |
— | |||||||
Deferred offering costs associated with the proposed public offering |
— | |||||||
|
|
|
|
|||||
Total Assets |
$ |
$ |
||||||
|
|
|
|
|||||
Liabilities and Stockholders’ Equity: |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | — | |||||
Accrued expenses |
— | |||||||
Franchise tax payable |
— | |||||||
Note payable—related party |
— | |||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Derivative warrant liabilities |
— | |||||||
|
|
|
|
|||||
Total liabilities |
||||||||
Commitments and Contingencies |
||||||||
Common stock, $ - |
— | |||||||
Stockholders’ Equity: |
||||||||
Preferred stock, $ |
||||||||
Common stock, $ -0- |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
Total Liabilities and Stockholders’ Equity |
$ |
$ |
||||||
|
|
|
|
For the three months ended June 30, 2021 |
For the six months ended June 30, 2021 |
For the period from May 27, 2020 (inception) through June 30, 2020 |
||||||||||
General and administrative expenses |
$ | $ | $ | |||||||||
Administrative expenses—related party |
||||||||||||
Franchise tax expense |
||||||||||||
|
|
|
|
|
|
|||||||
Loss from operations |
( |
) | ( |
) | ( |
) | ||||||
Other income (expenses) |
||||||||||||
Change in fair value of derivative warrant liabilities |
( |
) | ( |
) | ||||||||
Net gain from investments held in Trust Account |
— | |||||||||||
|
|
|
|
|
|
|||||||
Total other income (expenses) |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
Net loss |
$ | ( |
$ | ( |
$ | ( |
||||||
|
|
|
|
|
|
|||||||
Basic and diluted weighted average shares outstanding of Public Shares of common stock subject to possible redemption |
||||||||||||
|
|
|
|
|
|
|||||||
Basic and diluted net income per share, Public Shares of common stock subject to possible redemption |
||||||||||||
|
|
|
|
|
|
|||||||
Basic and diluted weighted average shares outstanding of non-redeemable common stock |
||||||||||||
|
|
|
|
|
|
|||||||
Basic and diluted net loss per share, non-redeemable common stock |
$ | ( |
$ | ( |
$ | ( |
||||||
|
|
|
|
|
|
Common Stock |
Additional Paid- In Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance—December 31, 2020 |
$ |
$ |
$ |
( |
$ |
|||||||||||||||
Sale of units in initial public offering, less fair value of public warrants |
— | |||||||||||||||||||
Offering costs |
— | — | ( |
) | — | ( |
) | |||||||||||||
Sale of units in private placement, less derivative warrant liabilities |
— | |||||||||||||||||||
Common stock subject to possible redemption |
( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance—March 31, 2021 (unaudited) |
$ |
$ |
$ |
( |
$ |
|||||||||||||||
Common stock subject to possible redemption |
— | |||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance—June 30, 2021 (unaudited) |
$ |
$ |
$ |
( |
$ |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance—May 27, 2020 (inception) |
$ |
$ |
$ |
$ |
||||||||||||||||
Issuance of common stock to Sponsor |
— | |||||||||||||||||||
Net loss |
— | — | — | ( |
) | — | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance—June 30, 2020 |
$ |
$ |
$ |
( |
$ |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30, 2021 |
For the period from May 2020 (inception) through June 30, 2020 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | ( |
) |
$ | ( |
) | ||
Adjustments to reconcile net loss |
||||||||
General and administrative expenses paid by related party under promissory note |
||||||||
Change in fair value of derivative warrant liabilities |
||||||||
Net gain from investments held in Trust Account |
( |
) | ||||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
( |
) | ||||||
Account payable |
||||||||
Accrued expenses |
||||||||
Franchise tax payable |
||||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) | ||||||
|
|
|
|
|||||
Cash Flows from Investing Activities |
||||||||
Cash deposited in Trust Account |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) | ||||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Repayment of note payable to related party |
( |
) | ||||||
Proceeds received from initial public offering, gross |
— | |||||||
Proceeds received from private placement |
— | |||||||
Offering costs paid |
( |
) | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
||||||||
|
|
|
|
|||||
Net change in cash |
||||||||
Cash - beginning of the period |
||||||||
|
|
|
|
|||||
Cash - end of the period |
$ |
$ | ||||||
|
|
|
|
|||||
Supplemental disclosure of noncash activities: |
||||||||
Offering costs included in accrued expenses |
$ | $ | ||||||
|
|
|
|
|||||
Offering costs paid by related party under promissory note |
$ | $ | ||||||
|
|
|
|
|||||
Initial value of common stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Change in value of common stock subject to possible redemption |
$ | ( |
) | $ | |
|||
|
|
|
|
|
|
|
|
|
Deferred offering costs paid by Sponsor in exchange for common stock |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
• | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For the three months ended June 30, 2021 |
For the six months ended June 30, 2021 |
|||||||
Common stock subject to possible redemption |
||||||||
Numerator: Earnings allocable to common stock subject to possible redemption |
||||||||
Net gain from investments held in Trust Account |
$ | $ | ||||||
Less: Company’s portion available to be withdrawn to pay taxes |
( |
) | ( |
) | ||||
Net income attributable to Class A common stock subject to possible redemption |
$ | $ | ||||||
Denominator: Weighted average Class A common stock subject to possible redemption |
||||||||
Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption |
||||||||
Basic and diluted net income per share, Class A common stock subject to possible redemption |
$ |
$ |
||||||
Non-redeemable common stock |
||||||||
Numerator: Net Loss minus Net Earnings |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Net income allocable to Class A common stock subject to possible redemption |
||||||||
Non-redeemable net loss |
$ |
( |
) |
$ |
( |
) | ||
Denominator: weighted average non-redeemable common stock |
||||||||
Basic and diluted weighted average shares outstanding, non-redeemable common stock |
||||||||
Basic and diluted net loss per share, non-redeemable common stock |
$ |
( |
) |
$ |
( |
) | ||
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of |
• | if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any |
• | if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such Public Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets—Investments held in Trust Account: |
||||||||||||
Mutual funds |
$ | $ | — | $ | — | |||||||
U.S. Treasury Securities |
$ | |
$ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Derivative warrant liabilities—Private |
$ | — | $ | — | $ | |
As of February 2, 2021 |
As of March 31, 2021 |
As of June 30, 2021 |
||||||||||
Volatility |
% | |
|
% |
|
% | ||||||
Stock price |
$ | $ |
|
|
$ | |||||||
Expected life of the options to convert |
|
|
|
|
||||||||
Risk-free rate |
% | |
|
% |
|
% | ||||||
Dividend yield |
% | |
|
% |
|
% |
Level 3—Derivative warrant liabilities at December 31, 2020 |
$ | |||
Issuance of Private Warrants |
||||
Change in fair value of derivative warrant liabilities |
||||
|
|
|||
Level 3—Derivative warrant liabilities at March 31, 2021 |
$ | |
||
Change in fair value of derivative warrant liabilities |
||||
|
|
|||
Level 3—Derivative warrant liabilities at June 30, 2021 |
$ | |||
|
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds. |
Item 3. |
Defaults upon Senior Securities |
Item 4. |
Mine Safety Disclosures. |
Item 5. |
Other Information. |
Item 6. |
Exhibits. |
* | These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
Dated: August 16, 2021 | BROOKLINE CAPITAL ACQUISITION CORP. | |||||
By: | /s/ Dr. Samuel P. Wertheimer | |||||
Name: | Dr. Samuel P. Wertheimer | |||||
Title: | Chief Executive Officer and Chairman |